Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has approved Mirapex ER® extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson’s disease (PD).
MIRAPEX ER is not indicated in advanced PD. Parkinson’s disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.
“MIRAPEX ER for early Parkinson’s disease is a positive development in the treatment of this disease. This new, once-daily treatment has a more convenient dosing schedule, offering greater flexibility as someone with early Parkinson’s disease plans his or her day,” said Robert Hauser, M.D., professor of Neurology, and director, Parkinson’s Disease & Movement Disorders Center at the University of South Florida College of Medicine. “In general, patients often prefer once-daily dosing to a more frequent regimen because of convenience.”